StockData

Zhengye Biotechnology Holding Ltd (ZYBT) stock

ZYBTNasdaqPharmaceutical Preparations
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 28, 2026Score 4/30
$1.52+0.09 (+6.29%)

Close on Nov 17, 2026Market cap $72.03MP/E –Yield –

Zhengye Biotechnology gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2025 it was 20.5%, against 49.0% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202520.5%−28.5
FY2024Dec 31, 202449.0%−6.5
FY2023Dec 31, 202355.5%−1.3
FY2022Dec 31, 202256.8%–

More Zhengye Biotechnology figures

See a number that looks wrong?